's () Richard Marsden joins Proactive London's Katie Pilbeam to discuss three news updates so far this year.
Begining with the first patient dosed with its inhaled formulation of interferon beta-1a as part of its global phase III trial in people hospitalised coronavirus (COVID-19).
Secondly, they have put their last patient into their home trial, which means patients don't have to leave their homes at all, ideal for the current lockdown circumstances, all visits are conducted on a zoom call.
And finally, it's inhaled interferon beta-1a respiratory treatment has been included in a US government-sponsored coronavirus (COVID-19) clinical trial.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE